SV2A and Parkinson disease: These include agents targeting neuroinflammation (e.g., TSPO ligands), synaptic density (e.g., SV2A ligands), mitochondrial dysfunction, and, most notably, α-synuclein (α-Syn) aggregation, the pathological hallmark of PD [7,8,9,10].